Optimal Antithrombotic Therapy in Patients with Atrial Fibrillation During Percutaneous Coronary Intervention

Bibliography link: Barbarash O.L., Kashtalap V.V. Optimal Antithrombotic Therapy in Patients with Atrial Fibrillation During Percutaneous Coronary Intervention. Doctor.Ru. 2020; 19(5): 6–13. (in Russian) DOI: 10.31550/1727-2378-2020-19-5-6-13
22 July 15:42

Objective of the Review: to analyse current American and European recommendations and to present modern approaches to prescription of antithrombotic medicines to patients with atrial fibrillation during percutaneous coronary interventions.

Key Points. Key results of international clinical studies to compare safety and efficiency of triple and double antithrombotic therapy (ATT) are presented. Addressed are the current clinical opinions triggering questions asked by practicians as regards prescription and later withdrawal of acetylsalicylic acid (ASA), use of Clopidogrel and novel antiaggregants in double and triple ATT.

Conclusion. Rational use of both triple (oral anticoagulant (OAC) + Clopidogrel + ASA) and double ATT (OAC+ P2Y12 platelet receptor inhibitor). The triple therapy duration should be reduced as much as possible; all recommendations give preference to double therapy, and in a number of consensus papers, double therapy is a therapy of choice for the majority of patients.

Contributions: Barbarash, O.L. — general concept, text preparation and final review; Kashtalap, V.V. — analytical comparison of the current American and European clinical recommendations.

Conflict of interest: The authors declare that they do not have any conflict of interests.

O.L. Barbarash (Corresponding author) — Scientific and Research Institute of Complex Cardiovascular Problems; 6 Sosnovyi Blvd., Kemerovo, Russian Federation 650002. Federal State-Funded Educational Institution of Higher Education "Kemerovo State Medical University" of the Ministry of Health of the Russian Federation; 22A Voroshilova Str., Kemerovo, Russian Federation 650056. eLIBRARY.RU SPIN: 5373-7620. ORCID: E-mail:

V.V. Kashtalap — Scientific and Research Institute of Complex Cardiovascular Problems; 6 Sosnovyi Blvd., Kemerovo, Russian Federation 650002. eLIBRARY.RU SPIN: 8816-7409. ORCID:Х. E-mail:


Comparison of the American and European approaches to prescription of antithrombotic therapy in atrial fibrillation and percutaneous coronary intervention (PCI) [2]


Note: TT — triple therapy (oral anticoagulant (OAC) + Clopidogrel + ASA), DT — double therapy (OAC+ P2Y12 inhibitor).

Received: 06.04.2020
Accepted: 10.05.2020

22 July 15:42
  1. Piepoli M.F., Hoes A.W., Agewall S., Albus C., Brotons C., Catapano A.L. et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The sixth Joint Task force of the European society of Cardiology and Other societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & rehabilitation (eACPr). Eur. Heart J. 2016; 37(29): 2315–81. DOI: 10.1093/eurheartj/ehw106
  2. Buccheri S., Angiolillo D.J., Capodanno D. Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. Ther. Adv. Cardiovasc. Dis. 2019; 13: 1753944719891688. DOI: 10.1177/1753944719891688
  3. Zoni-Berisso M., Lercari F., Carazza T., Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clin. Epidemiol. 2014; 6: 213–20. DOI: 10.2147/CLEP.S47385
  4. Freedman J.E., Gersh B.J. Atrial fibrillation and stroke prevention in aging patients: what’s good can be even better. Circulation. 2014; 130(2): 129–31. DOI: 10.1161/CIRCULATIONAHA.114.010873
  5. Michniewicz E., Mlodawska E., Lopatowska P., Tomaszuk-Kazberuk A., Malyszko J. Patients with atrial fibrillation and coronary artery disease — double trouble. Adv. Med. Sci. 2018; 63(1): 30–5. DOI: 10.1016/j.advms.2017.06.005
  6. Capodanno D., Huber K., Mehran R., Lip G.Y.H., Faxon D.P., Granger C.B. et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019; 74(1): 83–99. DOI: 10.1016/j.jacc.2019.05.016
  7. Alekyan B.G., Karapetyan N.G. Modern Russian trends in endovascular and surgical treatment of some isolated heart diseases. Russian Journal of Endovascular Surgery. 2019; 6(2): 98–106. (in Russian). DOI: 10.24183/2409-4080-2019-6-2-98-106
  8. Bokeriya L.A., Milievskaya E.B., Kudzova Z.F., Priannishnikov V.V. Cardiovascular surgery — 2017. Diseases and congenital abnormalities of the circulatory system. M.: A.N. Bakulev National Medical Research Center of Cardiovascular Surgery; 2018. 252 p. (in Russian)
  9. Lip G.Y.H., Collet J.-P., Haude M., Byrne R., Chung E.H., Fauchier L. et al. 2018 joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). Europace. 2019; 21(2): 192–3. DOI: 10.1093/europace/euy174
  10. Shanmugasundaram M., Hashemzadeh M., Movahed M. Outcomes of percutaneous coronary intervention in patients with atrial fibrillation. J. Am. Coll. Cardiol. 2018; 71(11 suppl.): A1024. DOI: 10.1016/S0735-1097(18)31565-1
  11. Huisman M.V., Rothman K.J., Paquette M., Teutsch C., Diener H.-C., Dubner S.J. et al. The changing landscape for stroke prevention in AF: findings from the GLORIA-AF registry Phase 2. J. Am. Coll. Cardiol. 2017; 69(7): 777–85. DOI: 10.1016/j.jacc.2016.11.061
  12. Loukianov M.M., Boytsov S.A., Yakushin S.S., Martsevich S.Y., Vorobyev A.N., Zagrebelnyy A.V. et al. Diagnostics, treatment, associated cardiovascular and concomitant non-cardiac diseases in patients with diagnosis of “atrial fibrillation” in real outpatient practice (according to data of registry of cardiovascular diseases, RECVASA). Rational Pharmacotherapy in Cardiology. 2014; 10(4): 366–77. (in Russian). DOI: 10.20996/1819-6446-2014-10-4-366-377
  13. Polshakova I.L., Povetkin S.V. Drug therapy structure and clinical characteristics of patients with atrial fibrillation according to data of REKUR-AF Study. Rational Pharmacotherapy in Cardiology. 2018; 14(5): 733–40. (in Russian). DOI: 10.20996/1819-6446-2018-14-5-733-740
  14. Kashtalap V.V., Barbarash O.L. Actual problems of antithrombotic therapy in acute coronary syndrome (following the material presented at the European society of cardiology congress 2017). Medical Council. 2017; 12: 82–8. (in Russian). DOI: 10.21518/2079-701X-2017-12-82-88
  15. Valgimigli M., Bueno H., Byrne R.A., Collet J.P., Costa F., Jeppsson A. et al. Corrigendum to: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur. Heart J. 2018; 39(22): 2089. DOI: 10.1093/eurheartj/ehx638
  16. ACTIVE Writing Group of the ACTIVE Investigators; Connolly S., Pogue J., Hart R., Pfeffer M., Hohnloser S. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367(9526): 1903–12. DOI: 10.1016/S0140-6736(06)68845-4
  17. ACTIVE Investigators; Connolly S.J., Pogue J., Hart R.G., Hohnloser S.H., Pfeffer M. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 360(20): 2066–78. DOI: 10.1056/NEJMoa0901301
  18. Connolly S.J., Eikelboom J., Joyner C., Diener H.-C., Hart R., Golitsyn S. et al. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 2011; 364(9): 806–17. DOI: 10.1056/NEJMoa1007432
  19. Simmers M.B., Cole B.K., Ogletree M.L., Chen Z., Xu Y., Kong L.-J. et al. Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cells. Thromb. Res. 2016; 143: 34–9. DOI: 10.1016/j.thromres.2016.04.022
  20. Capodanno D., Angiolillo D.J. Triple antithrombotic therapy at the intercept between threats and opportunities: don’t throw out the baby with the bath water. JACC Cardiovasc. Interv. 2017; 10(11): 1086–8. DOI: 10.1016/j.jcin.2017.03.028
  21. van Rein N., Heide-Jørgensen U., Lijfering W.M., Dekkers O.M., Sørensen H.T., Cannegieter S.C. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation. 2019; 139(6): 775–86. DOI: 10.1161/CIRCULATIONAHA.118.036248
  22. Sørensen R., Hansen M.L., Abildstrom S.Z., Hvelplund A., Andersson C., Jørgensen C. et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374(9706): 1967–74. DOI: 10.1016/S0140-6736(09)61751-7
  23. Lopes R.D., Hong H., Harskamp R.E., Bhatt D.L., Mehran R., Cannon C.P. et al. Optimal antithrombotic regimens for patients with atrial fibrillation undergoing percutaneous coronary intervention: an updated network meta-analysis. JAMA Cardiol. 2020; 5(5): 1–8. DOI: 10.1001/jamacardio.2019.6175
  24. Connolly S.J. Anticoagulant-related bleeding and mortality. J. Am. Coll. Cardiol. 2016; 68(23): 2522–4. DOI: 10.1016/j.jacc.2016.10.005
  25. Mehran R., Pocock S.J., Stone G.W., Clayton T.C., Dangas G.D., Feit F. et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur. Heart J. 2009; 30(12): 1457–66. DOI: 10.1093/eurheartj/ehp110
  26. Généreux P., Giustino G., Witzenbichler B., Weisz G., Stuckey T.D., Rinaldi M.J. et al. Incidence, predictors, and impact of postdischarge bleeding after percutaneous coronary intervention. J. Am. Coll. Cardiol. 2015; 66(9): 1036–45. DOI: 10.1016/j.jacc.2015.06.1323
  27. Lip G.Y.H. The safety of NOACs in atrial fibrillation patient subgroups: a narrative review. Int. J. Clin. Pract. 2019; 73(2): e13285. DOI: 10.1111/ijcp.13285
  28. Writing Group Members; January C.T., Wann L.S., Calkins H., Chen L.Y., Cigarroa J.E. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. 2019; 16(8): e66–93. DOI: 10.1016/j.hrthm.2019.01.024
  29. Neumann F.J., Sousa-Uva M., Ahlsson A., Alfonso F., Banning A.P., Benedetto U. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. ESC Scientific Document Group. Eur. Heart J. 2019; 40(2): 87–165. DOI: 10.1093/eurheartj/ehy394
  30. Kirchhof P., Benussi S., Kotecha D., Ahlsson A., Atar D., Casadei B. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016; 18(11): 1609–78. DOI: 10.1093/europace/euw295
  31. Krivosheeva E.N., Kropacheva E.S., Panchenko E.P., Samko A.N. Thrombotic and hemorrhagic complications in atrial fibrillation patients, undergoing elective percutaneous coronary intervention. Therapeutic Archive. 2019; 91(9): 38–46. (in Russian). DOI: 10.26442/00403660.2019.09.000297
  32. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361(12): 1139–51. DOI: 10.1056/NEJMoa0905561
  33. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 2011; 365(10): 883–91. DOI: 10.1056/NEJMoa1009638
  34. Giugliano R.P., Ruff C.T., Braunwald E., Murphy S.A., Wiviott S.D., Halperin J.L. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2013; 369(22): 2093–104. DOI: 10.1056/NEJMoa1310907
  35. Granger C.B., Alexander J.H., McMurray J.J.V., Lopes R.D., Hylek E.M., Hanna M. et al. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2011; 365(11): 981–92. DOI: 10.1056/NEJMoa1107039
  36. Hicks T., Stewart F., Eisinga A. NOACs versus warfarin for stroke prevention in patients with AF: a systematic review and meta-analysis. Open Heart. 2016; 3(1): e000279. DOI: 10.1136/openhrt-2015-000279
  37. Gómez-Outes A., Lagunar-Ruíz J., Terleira-Fernández A.I., Calvo-Rojas G., Suárez-Gea M.L., Vargas-Castrillón E. Causes of death in anticoagulated patients with atrial fibrillation. J. Am. Coll. Cardiol. 2016; 68(23): 2508–21. DOI: 10.1016/j.jacc.2016.09.944
  38. Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014; 383(9921): 955–62. DOI: 10.1016/S0140-6736(13)62343-0
  39. Gibson C.M., Mehran R., Bode C., Halperin J., Verheugt F.W., Wildgoose P. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N. Engl. J. Med. 2016; 375(25): 2423–34. DOI: 10.1056/NEJMoa1611594
  40. Cannon C.P., Bhatt D.L., Oldgren J., Lip G.Y.H., Ellis S.G., Kimura T. et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N. Engl. J. Med. 2017; 377(16): 1513–24. DOI: 10.1056/NEJMoa1708454
  41. Chi G., Kerneis M., Kalayci A., Liu Y., Mehran R., Bode C. et al. Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: a bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. Am. Heart J. 2018; 203: 17–24. DOI: 10.1016/j.ahj.2018.06.003
  42. Lopes R.D., Heizer G., Aronson R., Vora A.N., Massaro T., Mehran R. et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N. Engl. J. Med. 2019; 380(16): 1509–24. DOI: 10.1056/NEJMoa1817083
  43. Vranckx P., Valgimigli M., Eckardt L., Tijssen J., Lewalter T., Gargiulo G. et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019; 394(10206): 1335–43. DOI: 10.1016/S0140-6736(19)31872-0
  44. Rossini R., Musumeci G., Lettieri C., Molfese M., Mihalcsik L., Mantovani P. et al. Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy. Am. J. Cardiol. 2008; 102(12): 1618–23. DOI: 10.1016/j.amjcard.2008.08.021
  45. Fanikos J., Burnett A.E., Mahan C.E., Dobesh P.P. Renal function considerations for stroke prevention in atrial fibrillation. Am. J. Med. 2017; 130(9): 1015–23. DOI: 10.1016/j.amjmed.2017.04.015
  46. Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol. Rev. 2011; 91(1): 265–325. DOI: 10.1152/physrev.00031.2009
  47. Hamatani Y., Ogawa H., Takabayashi K., Yamashita Y., Takagi D., Esato M. et al. Left atrial enlargement is an independent predictor of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Sci. Rep. 2016; 6: 31042. DOI: 10.1038/srep31042
  48. Chao T.F., Chiang C.E., Chen T.J., Lip G.Y.H., Chen S.-A. Reassessment of risk for stroke during follow-up of patients with atrial fibrillation. Ann. Intern. Med. 2019; 170(9): 663–4. DOI: 10.7326/M18-1177
  49. Schulz S., Schuster T., Mehilli J., Byrne R.A., Ellert J., Massberg S. et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur. Heart J. 2009; 30(22): 2714–21. DOI: 10.1093/eurheartj/ehp275
  50. Lagerqvist B., Carlsson J., Fröbert O., Lindbäck J., Scherstén F., Stenestrand U. et al. Stent thrombosis in Sweden: a report from the Swedish coronary angiography and angioplasty registry. Circ. Cardiovasc. Interv. 2009; 2(5): 401–8. DOI: 10.1161/CIRCINTERVENTIONS.108.844985
  51. Van Werkum J.W., Heestermans A.A., Zomer A.C., Kelder J.C., Suttorp M.-J., Rensing B.J. et al. Predictors of coronary stent thrombosis. The Dutch stent thrombosis registry. J. Am. Coll. Cardiol. 2009; 53(16): 1399–409. DOI: 10.1016/j.jacc.2008.12.055
  52. Dewilde W.J.M., Oirbans T., Verheugt F.W.A., Kelder J.C., De Smet B.J.G.L., Herrman J.-P. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381(9872): 1107–15. DOI: 10.1016/S0140-6736(12)62177-1
  53. Fiedler K.A., Maeng M., Mehilli J., Schulz-Schüpke S., Byrne R.A., Sibbing D. et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: The ISAR-TRIPLE Trial. J. Am. Coll. Cardiol. 2015; 65(16): 1619–29. DOI: 10.1016/j.jacc.2015.02.050
  54. Golwala H.B., Cannon C.P., Steg P.G., Doros G., Qamar A., Ellis S.G. et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur. Heart J. 2018; 39(19): 1726–35a. DOI: 10.1093/eurheartj/ehy162
  55. Capodanno D., Angiolillo D.J. Dual antithrombotic therapy for atrial fibrillation and PCI. Lancet. 2019; 394(10206): 1300–2. DOI: 10.1016/S0140-6736(19)31954-3
  56. Schömig A., Neumann F.-J., Kastrati A., Schühlen H., Blasini R., Hadamitzky M. et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 1996; 334(17): 1084–9. DOI: 10.1056/NEJM199604253341702
  57. Bertrand M.E., Legrand V., Boland J., Fleck E., Bonnier J., Emmanuelson H. et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation. 1998; 98(16): 1597–603. DOI: 10.1161/01.cir.98.16.1597
  58. Urban P., Macaya C., Rupprecht H.J., Kiemeneij F., Emanuelsson H., Fontanelli A. et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation. 1998; 98(20): 2126–32. DOI: 10.1161/01.cir.98.20.2126
  59. Leon M.B., Baim D.S., Popma J.J., Gordon P.C., Cutlip D.E., Ho K.K. et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N. Engl. J. Med. 1998; 339(23): 1665–71. DOI: 10.1056/NEJM199812033392303
  60. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Alfonso F., Macaya C., Bass T.A. et al. Variability in individual responsiveness to clopidogrel. J. Am. Coll. Cardiol. 2007; 49(14): 1505–16. DOI: 10.1016/j.jacc.2006.11.044
  61. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancetю 1996; 348(9038): 1329–39. DOI: 10.1016/s0140-6736(96)09457-3
  62. Bhatt D.L., Hirsch A.T., Ringleb P.A., Hacke W., Topol E.J. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE Investigators. Am. Heart J. 2000; 140(1): 67–73. DOI: 10.1067/mhj.2000.108239
  63. Knuuti J., Wijns W., Saraste A., Capodanno D., Barbato E., Funck-Brentano C. et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur. Heart J. 2020; 41(3): 407–77. DOI: 10.1093/eurheartj/ehz425
  64. Capodanno D., Alfonso F., Levine G.N., Valgimigli M., Angiolillo D.J. ACC/AHA versus ESC Guidelines on dual antiplatelet therapy: JACC Guideline comparison. J. Am. Coll. Cardiol. 2018; 72(23 PtA): 2915–31. DOI: 10.1016/j.jacc.2018.09
  65. Sarafoff N., Martischnig A., Wealer J., Mayer K., Mehilli J., Sibbing D. et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J. Am. Coll. Cardiol. 2013; 61(20): 2060–6. DOI: 10.1016/j.jacc.2013.02.036
  66. Angiolillo D.J., Goodman S.G., Bhatt D.L., Eikelboom J.W., Price M.J., Moliterno D.J. et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective — 2018 update. Circulation. 2018; 138(5): 527–36. DOI: 10.1161/CIRCULATIONAHA.118.034722
  67. Angiolillo D.J., Rollini F., Storey R.F., Bhatt D.L., James S., Schneider D.J. et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017; 136(20): 1955–75. DOI: 10.1161/CIRCULATIONAHA.117.031164
  68. Hamon M., Lemesle G., Tricot O., Meurice T., Deneve M., Dujardin X. et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J. Am. Coll. Cardiol. 2014; 64(14): 1430–6. DOI: 10.1016/j.jacc.2014.07.957
  69. Alexander J.H., Lopes R.D., Thomas L., Alings M., Atar D., Aylward P. et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur. Heart J. 2014; 35(4): 224–32. DOI: 10.1093/eurheartj/eht445
Новости мировой медицины! Свежие статьи из журнала! Будьте в курсе!

Похожие статьи

Similar article
19 April 00:00, Interview
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)
19 April 00:00, Paediatrics
A.V. Aksenov, E.A. Ivanovskaya
Successful Use of Tocilizumab in a Child with Systemic Juvenile Idiopathic Arthritis
Doctor.Ru Pediatrics. Vol. 20, No. 3 (2021)